PDK1 and cancer: The in-well kinase assay showed that the IC50 for DIC was 19.42 ± 0.032 μM, more than 150-fold lower than that for DCA (3.042 ± 0.087 mM), the most advanced PDK1 inhibitor in clinical trials for cancer therapy [48].